Complexes and combinations of fetuin with therapeutic agents

A pharmaceutical composition comprising:

• (A) an active component consisting essentially of glycosylated polypeptide selected from the group consisting of a mammalian fetuin, α-2-HS glycoprotein, and combinations thereof;
• and
• (B) a positively charged (at physiological pH) therapeutic compound selected from the formula:
• wherein R is independently selected from the group consisting of phenyl, pyridine, amino-substituted pyridine, purine, oxo-substituted purine, C1-6 alkyl-substituted purine, xanthine, pyrimidine, C1-6 alkyl-substituted pyrimidine, and oxo-substituted pyrimidine;
• wherein X2 is selected from the group consisting of H2N(CNH)—NH—N═CH—, H2N(CNH)—NH—N═C(CH3)—, and H—;
• wherein X1, X′1 X′2 are independently selected from the group consisting of H2N(CNH)—NH—N═CH— and H2N(CNH)—NH—N═C(CH3)—;
• wherein Z is selected from the group consisting of phenyl, pyridyl (C5NH3), —NH(CO)NH—, straight or branched C2-10 alkyl, straight or branched C2-10 alkenyl, —A— straight or branched C2-10 alkyl —A—, —A— straight or branched C2-10 alkenyl —A—, and —A—, wherein A is independently selected from the group consisting of —NH(CO)—, —(CO)NH—, —NH(CO)NH—, —NH—, and —O—;
• and
• (C) a pharmaceutically acceptable carrier.

A therapeutic combination of glycosylated polypeptide and a positively charged (at physiological pH) therapeutic compound:

• wherein the glycosylated polypeptide is selected from the group consisting of a mammalian fetuin, α2-HS glycoprotein, and combinations thereof;
• and
• wherein the positively charged (at physiological pH) therapeutic compound is selected from the formula:
• wherein R is independently selected from the group consisting of phenyl, pyridine, amino-substituted pyridine, purine, oxo-substituted purine, C1-6 alkyl-substituted purine, xanthine, pyrimidine, C1-6 alkyl-substituted pyrimidine, and oxo-substituted pyrimidine;
• wherein X2 is selected from the group consisting of H2N(CNH)—NH—N═CH—, H2N(CNH)—NH—N═C(CH3)—, and H—;
• wherein X1, X′1 X′2 are independently selected from the group consisting of H2N(CNH)—NH—N═CH— and H2N(CNH)—NH—N═C(CH3)—;
• wherein Z is selected from the group consisting of phenyl, pyridyl (C5NH3), —NH(CO)NH—, straight or branched C2-10 alkyl, straight or branched C2-10 alkenyl, —A— straight or branched C2-10 alkyl —A—, —A— straight or branched C2-10 alkenyl —A—, and —A—, wherein A is independently selected from the group consisting of —NH(CO)—, —(CO)NH—, —NH(CO)NH—, —NH—, and —O—.